Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ enriched peripheral blood hematopoietic stem cells
- Development stage
- Phase 1
- Lead developer
- CellPro
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ enriched peripheral blood hematopoietic stem cells (PBSC) is an investigational cellular therapy developed by Northwestern University for the treatment of hematologic malignancies. This therapy involves the isolation and enrichment of hematopoietic stem and progenitor cells expressing the CD34 surface marker from a donor's peripheral blood using immunomagnetic selection. In the clinical trial context, these enriched cells are used to augment unmanipulated bone marrow in allogeneic transplantation. The mechanism of action relies on the ability of these stem cells to home to the recipient's bone marrow and differentiate into all hematopoietic lineages, thereby reconstituting the blood and immune systems following myeloablative conditioning. The enrichment of CD34+ cells is intended to optimize the graft composition to improve engraftment kinetics and potentially modulate the risk of graft-versus-host disease.
- Other names
- CD34+ enriched PBSCCD34+ selected peripheral blood stem cellsCD34+ enriched peripheral blood stem cells
Beyond the preview
Go deeper on CD34+ enriched peripheral blood hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ enriched peripheral blood hematopoietic stem cells.